Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eledon Pharmaceuticals, Inc. (ELDN) had Return on Tangible Equity of -5.67% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-6.50M |
|
-- |
|
-- |
|
$17.96M |
|
$-17.96M |
|
$11.47M |
|
$-6.50M |
|
$-6.50M |
|
$-6.50M |
|
$-6.50M |
|
$-6.50M |
|
$-6.50M |
|
$-17.96M |
|
$-17.89M |
|
77.13M |
|
77.13M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$127.72M |
|
-- |
|
$33.59M |
|
$161.31M |
|
$9.19M |
|
-- |
|
$37.54M |
|
$46.73M |
|
$114.58M |
|
$114.58M |
|
$114.58M |
|
59.88M |
|
| Cash Flow Statement Financials | |
$-16.06M |
|
$3.89M |
|
$0.12M |
|
$20.55M |
|
$8.50M |
|
$-12.05M |
|
$2.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.67% |
|
|
Return on Tangible Equity |
-5.67% |
-4.03% |
|
-5.67% |
|
$1.91 |
|
$-0.21 |
|
$-0.21 |
|